Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

ALLOPLUS: allogeneic hematopoietic stem cell transplantation in children and adult people living with human immunodeficiency virus, a retrospective study of the SFGM-TC.

Bone marrow transplantation·2026
Same author

A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia.

Bone marrow transplantation·2026
Same author

Prognostic impact of intensive chemotherapy in patients with TP53-mutated AML.

Blood cancer journal·2026
Same author

Outpatient Rescue With Stem Cells Boost for Refractory Hematotoxicity Following anti-BCMA CAR T-Cell Therapy: A Case Report.

Case reports in hematology·2026
Same author

Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT.

Bone marrow transplantation·2026
Same author

Ultra-high-sensitivity next-generation sequencing-based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort.

Blood cancer journal·2026

相关实验视频

Updated: Jun 16, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K

作为诱导后AML治疗的中间剂量cytarabine.

Mathilde Hunault1, Cécile Pautas2, Sarah Bertoli3

  • 1Department of Hematology, Centre Hospitalier Universitaire (CHU) d'Angers, Centre de Recherche en Cancérologie et Immunologie Intégré de Nantes/Angers (CRCI2NA), Institut National de la Santé et de la Recherche Médical (INSERM) - Unit U1307, Centre National de la Recherche Scientifique (CNRS) - Unit UMR6075, Fédération Hospitalo-Universitaire Grand Ouest Against Leukemia (GOAL), Université d'Angers, Angers, France.

NEJM evidence
|June 24, 2025
PubMed
概括
此摘要是机器生成的。

在新诊断的急性骨髓性白血病 (AML) 患者中,中剂量细胞氨基酸 (IDAC) 的整体存活率与高剂量细胞氨基酸 (HDAC) 相比不差. 这项研究发现IDAC具有类似或较低的毒性,使其成为可行的诱导后治疗选择.

更多相关视频

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.5K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

284

相关实验视频

Last Updated: Jun 16, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.5K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

284

科学领域:

  • 血液学 血液学 血液学
  • 在瘤学瘤学.
  • 临床试验 临床试验

背景情况:

  • 急性髓性白血病 (AML) 是一种严重的血液性恶性瘤.
  • 诱导后化疗在AML治疗中起着至关重要的作用.
  • 为了优化患者的治疗结果,比较不同的细胞氨酸剂量策略至关重要.

研究的目的:

  • 评估中剂量细胞氨酸 (IDAC) 与高剂量细胞氨酸 (HDAC) 在整体生存 (OS) 中的非劣势性.
  • 评估IDAC与HDAC相比作为AML的诱导后治疗的安全性和毒性概况.
  • 为了确定IDAC在特定成年患者队列中的有效性.

主要方法:

  • 进行了一项随机对照试验,涉及18至60岁的新诊断AML的患者.
  • 患者接受了诱导后的IDAC (1500 mg/m2/12小时) 或HDAC (3000 mg/m2/12小时).
  • 总体存活率 (OS) 是主要终点,分析对欧洲白血病网络 (ELN) 2022 风险组进行了调整,使用了 antracycline,诱导反应和全原干细胞移植 (HSCT).

主要成果:

  • 在5年后,OS为IDAC的59.3%,而HDAC的57.5%,表明非劣势性 (调整后危险比,0.96;P=0.0042).
  • 治疗效果和患者亚组 (例如ELN 2022风险组) 之间没有发现显著的相互作用.
  • 与HDAC相比,IDAC与骨髓抑制的严重程度较低,相关不良事件较少.

结论:

  • 在新诊断的AML患者中,中剂量细胞氨基酸 (IDAC) 与高剂量细胞氨基酸 (HDAC) 相比,提供非劣质的整体生存结果.
  • IDAC证明了具有相似或降低毒性的有利安全概况.
  • 这些发现支持IDAC作为AML的有效和潜在的更安全的诱导后治疗选择.